V. Bulteel

Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease

P. Rutgeerts, M. Noman, J. Ceuppens, 2002, American Journal of Gastroenterology.

Anti-Saccharomyces Cerevisiae Antibodies (ASCA), Phenotypes of IBD, and Intestinal Permeability: A Study in IBD Families

P. Rutgeerts, S. Vermeire, B. Geypens, 2001, Inflammatory bowel diseases.

Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures

L. Dupont, H. Janssens, S. van Koningsbruggen-Rietschel, 2021, Trials.

Hyperresponsiveness of the Mucosal Barrier in Crohn's Disease Is Not Tumor Necrosis Factor‐Dependent

P. Rutgeerts, S. Vermeire, M. Noman, 2005, Inflammatory bowel diseases.

SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network

L. Dupont, S. van Koningsbruggen-Rietschel, V. Bulteel, 2020, European Respiratory Journal.

Effects of T cell‐induced colonic inflammation on epithelial barrier function†

P. Rutgeerts, G. Van Assche, J. Ceuppens, 2010, Inflammatory bowel diseases.

"Il faut continuer à poser des questions" patient reported outcome measures in cystic fibrosis: An anthropological perspective.

P. Burgel, I. Sermet-Gaudelus, J. Bend, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Pouchitis, Similar to Active Ulcerative Colitis, Is Associated with Impaired Butyrate Oxidation by Intestinal Mucosa

P. Rutgeerts, K. Verbeke, V. De Preter, 2009, Inflammatory bowel diseases.

In vivo Influence of Nicotine on Human Basal and NSAID-induced Gut Barrier Function

P. Rutgeerts, B. Geypens, P. Suenaert, 2003, Scandinavian journal of gastroenterology.

Disease-specific clinical trials networks: the example of cystic fibrosis

I. Fajac, K. De Boeck, V. Bulteel, 2016, European Journal of Pediatrics.

Developing an international network for clinical research: the European Cystic Fibrosis Society - Clinical Trials Network experience

C. Castellani, I. Fajac, V. Bulteel, 2011 .